Impact of cytotoxic and targeted antineoplastic drugs on the validity of the mitogen-induced interferon-gamma release assay for latent tuberculosis infection: Results of a prospective trial at a comprehensive cancer center

References

• Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer 1974; 33:850–8.
   PubMed Web of Science ®Google Scholar
• De La Rosa GR, Jacobson KL, Rolston KV, Raad II, Kontoyiannis DP, Safdar A. Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990–2000. Clin Microbiol Infect 2004;10:749–52.
   PubMed Web of Science ®Google Scholar
• Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006;42:1592–5.
   PubMed Web of Science ®Google Scholar
• Kucukardali Y, Oncul O, Cavuslu S, Danaci M, Calangu S, Erdem H, et al. Fever of Unknown Origin Study Group. The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. Int J Infect Dis 2008;12:71–9.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Losi M, D’Amico R, Luppi M, Ferrari A, Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136:198–204.
   PubMed Web of Science ®Google Scholar
• Aisenberg GM, Jacobson K, Chemaly RF, Rolston KV, Raad II, Safdar A. Extrapulmonary tuberculosis active infection misdiagnosed as cancer: Mycobacterium tuberculosis disease in patients at a comprehensive cancer center (2001–2005). Cancer 2005;104:2882–7.
   PubMed Web of Science ®Google Scholar
• Malone JL, Ijaz K, Lambert L, Rosencrans L, Phillips L, Tomlinson V, et al. Investigation of healthcare-associated transmission of Mycobacterium tuberculosis among patients with malignancies at three hospitals and at a residential facility. Cancer 2004;101:2713–21.
   PubMed Web of Science ®Google Scholar
• Stefan DC, Dippenaar A, Detjen AK, Schaaf HS, Marais BJ, Kriel B, et al. Interferon-gamma release assays for the detection of Mycobacterium tuberculosis infection in children with cancer. Int J Tuberc Lung Dis 2010;14:689–94.
   PubMed Web of Science ®Google Scholar
• Britton WJ, Gilbert GL, Wheatley J, Leslie D, Rothel JS, Jones SL, et al. Sensitivity of human gamma interferon assay and tuberculin skin testing for detecting infection with Mycobacterium tuberculosis in patients with culture positive tuberculosis. Tuberculosis (Edinb) 2005;85:137–45.
   PubMed Web of Science ®Google Scholar
• Piana F, Codecasa LR, Cavallerio P, Ferrarese M, Migliori GB, Barbarano L, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006;28:31–4.
   PubMed Web of Science ®Google Scholar
• Kim SY, Jung GS, Kim SK, Chang J, Kim MS, Kim YS, et al. Comparison of the tuberculin skin test and interferon-γ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection 2013;41:103–10.
   PubMed Web of Science ®Google Scholar
• Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677–86.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report 2000: health systems; improving performance. Geneva, Switzerland: WHO; 2000.
   Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional facilities: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1996;45: 1–27.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1995;44:18–34.
   Google Scholar
• Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Diseases Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376–95.
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1–25.
   PubMedGoogle Scholar
• Food and Drug Administration. T-SPOT-TB – P070006. FDA;Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/ucm102794.htm (accessed 16 June 2010).
   Google Scholar
• Lee SW, Oh DK, Lee SH, Kang HY, Lee CT, Yim JJ. Time interval to conversion of interferon-gamma release assay after exposure to tuberculosis. Eur Respir J 2011;37:1447–52.
   PubMed Web of Science ®Google Scholar
• Kim SY, Park MS, Kim YS, Kim SK, Chang J, Kang YA. Conversion rates of an interferon-γ release assay and the tuberculin skin test in the serial monitoring of healthcare workers. Infection 2013;41:511–6.
   PubMed Web of Science ®Google Scholar
• Lee SW, Lee SH, Yim JJ. Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. Infection 2012;40:431–5.
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Sepkowitz KA. Interferon gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188:422–31.
   Google Scholar
• Stern JN, Keskin DB, Romero V, Zuniga J, Encinales L, Li C, et al. Molecular signatures distinguishing active from latent tuberculosis in peripheral blood mononuclear cells, after in vitro antigenic stimulation with purified protein derivative of tuberculin (PPD) or Candida: a preliminary report. Immunol Res 2009;45:1–12.
   PubMed Web of Science ®Google Scholar
• Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373–9.
   PubMed Web of Science ®Google Scholar
• Franquet T, Müller NL, Giménez A, Martínez S, Madrid M, Domingo P. Infectious pulmonary nodules in immunocompromised patients: usefulness of computed tomography in predicting their etiology. J Comput Assist Tomogr 2003; 27:461–8.
   PubMed Web of Science ®Google Scholar
• Hofmeyr A, Lau WF, Slavin MA. Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberculosis (Edinb) 2007;87:459–63.
   PubMed Web of Science ®Google Scholar
• Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med 2008;49:186–94.
   PubMed Web of Science ®Google Scholar